SuperworthNuvation Bio NUVB
- Market cap
- $1.6B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 9.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $169.9M
- growth n/m, growth from a base too small to compare
- Net margin
- −88.2%
- Free cash flow yield
- n/m
- not a meaningful number
Nuvation Bio trades at 9.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $169.9M over the last twelve months with a −88% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $1.4M | $727K | $5.7M | $3.1M | $4.8M+237% | $13.1M+1705% | $41.9M+633% | $83.2M+2599% | $31.7M+556% | |
| Cost of revenue | n/a | n/a | $0 | $1.3M | $1.5M | $4.2M | $2.1M | $2.6M+91% | $3.3M+121% | n/a | n/a | n/a |
| Gross profit | $0 | $0 | $0 | $88K | −$788K | $1.5M | $990K | $2.3M+2465% | $9.8M | n/a | n/a | n/a |
| R&D | $18.6M−13% | $15.4M−9% | $12.8M−32% | $29.2M+57% | $27.7M+49% | $29.3M+91% | $24.6M+92% | $27.4M−6% | $28.8M+4% | $34.3M+17% | $35M+43% | $30.7M+12% |
| SG&A | $7.8M−3% | $5.5M−27% | $7.4M−5% | $16.2M+114% | $19.6M+152% | $26.1M+377% | $35.4M+381% | $38.5M+138% | $37.4M+91% | $40.3M+54% | $38.3M+8% | $42.6M+11% |
| −$26.3M−10% | −$20.8M−14% | −$20.2M−24% | −$470.4M+1700% | −$48.1M+83% | −$53.9M+159% | −$59M+192% | −$63.6M−87% | −$56.4M+17% | −$34M−37% | $3.9M | −$51M−20% | |
| Interest expense | $0 | $0 | $0 | $132K | $120K | $89K | $54K | $421K+219% | $6.5M+5345% | $6.7M+7398% | $6.7M+12322% | $6.8M+1506% |
| Pre-tax income | −$19.6M−28% | −$13.8M−34% | −$14.8M−32% | −$462.5M+2141% | −$41.2M+110% | −$49.4M+259% | −$53.2M+260% | −$59M−87% | −$55.8M+35% | −$36.6M−26% | $5.4M | −$62.8M+7% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$19.6M−28% | −$13.8M−34% | −$14.8M−32% | −$462.5M+2141% | −$41.2M+110% | −$49.4M+259% | −$53.2M+260% | −$59M−87% | −$55.8M+35% | −$36.6M−26% | $5.4M | −$62.8M+7% |
| −$0.09−25% | −$0.06−40% | −$0.07−30% | −$1.89+2000% | −$0.15+67% | −$0.15+150% | −$0.16+129% | −$0.17−91% | −$0.16+7% | −$0.11−27% | $0.01 | −$0.18+6% | |
| 218.9M+0% | 219M+0% | 219M+0% | 244.7M+12% | 273.6M+25% | 336.9M+54% | 338.6M+55% | 340.7M+39% | 342.4M+25% | 344.3M+2% | 377.5M+12% | 348.8M+2% |
Income tax: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Nuvation Bio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NUVBNuvation Bio | $1.6B | n/m | n/a | 9.4× | n/m | −88.2% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| Peer median | $1.5B | 12.5× | 17.9× | 2.0× | +11% | 13.3% |
Investors who own it
Investors we follow who held Nuvation Bio at the end of Jun 30, 2026, from their 13F filings.
- Stanley DruckenmillerDuquesne Family Office0.6% of portfolio
- David EinhornGreenlight Capital0.0% of portfolio
More on Nuvation Bio
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .